Cyfuse Biomedical K.K. (4892) AI Stock Analysis

Cyfuse Biomedical K.K.

(TSE/TYO:4892)

Select Model

Rating:48Neutral

Price Target:JPY 553.00▲(2.22% Upside)

Action:reiterated

Date:09/15/26

The overall score of 48 reflects a company with significant financial distress, as persistent losses and negative cash flows are the most critical risk factors. This is partially offset by strong short-term technical momentum, with the stock trading above key moving averages, though overbought indicators suggest caution. The negative P/E ratio further confirms a lack of earnings-based value. The company's early-stage commercialization shows promise in revenue growth, but it has not yet translated into financial stability.

Positive Factors

Revenue reboundThe sharp 2025 revenue rebound indicates renewed commercial activity for Cyfuse Biomedical’s platform and related offerings. If sustained, stronger sales can improve operating leverage, support broader customer adoption, and provide a larger base from which to develop regenerative-medicine applications.

Negative Factors

Deep operating lossesExtremely negative operating and net margins show that current revenue is far from covering the company’s cost base. Losses of this scale weaken the path to self-sustaining earnings, can erode equity over time, and make successful execution of future growth investments essential.

Cyfuse Biomedical K.K. (4892) vs. iShares MSCI Japan ETF (EWJ)

Market Cap: JPY 5.64B
Dividend Yield: ―
Average Volume (3M): 47.49K
Price to Earnings (P/E): -6.9
Beta (1Y): 0.33
Revenue Growth: 364.72%
EPS Growth: 18.43%
Country: Japan
Employees: 23
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Cyfuse Biomedical K.K. Business Overview & Revenue Model

Company Description

Established in 2010 and headquartered in Tokyo, Japan, Cyfuse Biomedical K.K. focuses on the creation, production, and distribution of regenerative medicine solutions. The company is actively involved in developing cell-based products for therapeutic...

How the Company Makes Money

Cyfuse Biomedical makes money primarily by commercializing its 3D cell assembly/bioprinting technology and related offerings. Key revenue streams include: (1) Sale or provision of access to its Regenova platform and associated hardware/systems used t...

Cyfuse Biomedical K.K. Financial Statement Overview

Summary

Financial health is weak. Revenue grew 253% to ¥231M, but gross margin fell to 33.9% and net loss was ¥764M with a -330% net margin. Operating and free cash flow are deeply negative, indicating significant cash burn. The balance sheet has a moderate 0.48 debt-to-equity ratio, but equity is declining due to accumulated losses. Persistent unprofitability and weak cash flow heavily weigh on this score.

Income Statement

25Negative

Balance Sheet

45Neutral

Cash Flow

20Very Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	305.90M	231.00M	54.45M	61.11M	374.48M	708.25M
Gross Profit	145.27M	78.40M	1.56M	-378.00K	223.93M	568.20M
EBITDA	-743.38M	-792.68M	-860.12M	-659.31M	-370.81M	89.07M
Net Income	-795.91M	-763.84M	-872.24M	-589.21M	-473.96M	142.91M
Balance Sheet
Total Assets	3.93B	4.27B	3.52B	4.21B	4.82B	2.65B
Cash, Cash Equivalents and Short-Term Investments	3.39B	3.73B	3.05B	3.87B	4.44B	2.41B
Total Debt	1.23B	1.31B	852.80M	913.00M	857.79M	569.06M
Total Liabilities	1.30B	1.51B	975.60M	1.01B	1.05B	746.12M
Stockholders Equity	2.62B	2.76B	2.54B	3.20B	3.77B	1.90B
Cash Flow
Free Cash Flow	0	-581.93M	-768.16M	-581.77M	-631.87M	161.54M
Operating Cash Flow	0	-534.79M	-760.55M	-562.30M	-403.60M	161.54M
Investing Cash Flow	0	-397.56M	-8.64M	-19.47M	-430.67M	-50.58M
Financing Cash Flow	0	1.26B	-52.01M	18.24M	2.66B	229.21M

Cyfuse Biomedical K.K. Technical Analysis

Technical Analysis SentimentNegative

Last Price541.00

Price Trends

50DMA607.60Negative

100DMA571.53Negative

200DMA605.05Negative

Market Momentum

MACD-16.71Positive

RSI33.86Neutral

STOCH14.78Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4892, the sentiment is Negative. The current price of 541.00 is below the 20-day moving average (MA) of 599.45, below the 50-day MA of 607.60, and below the 200-day MA of 605.05, indicating a bearish trend. The MACD of -16.71 indicates Positive momentum. The RSI at 33.86 is Neutral, neither overbought nor oversold. The STOCH value of 14.78 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4892.

Cyfuse Biomedical K.K. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

JP:4892 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
JP:7079	80Outperform	JPY 6.13B	0.94	―	3.73%	-11.16%	-21.80%
JP:4597	52Neutral	JPY 7.37B	-8.11	-53.67%	―	32.42%	61.00%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
JP:4892	48Neutral	JPY 5.64B	-6.87	―	―	364.72%	18.43%
JP:4539	47Neutral	JPY 5.47B	-44.12	―	3.30%	0.31%	-194.72%
JP:4883	42Neutral	JPY 3.18B	-1.17	―	―	―	-5.66%
JP:4582	39Underperform	JPY 3.72B	-0.48	―	―	-30.58%	6.93%

* Healthcare Sector Average

Performance Comparison

JP:4892 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
JP:4892	Cyfuse Biomedical K.K.	559.00	-26.00	-4.44%
JP:4597	Solasia Pharma KK	27.00	-6.00	-18.18%
JP:4539	Nippon Chemiphar Co., Ltd.	1515.00	30.29	2.04%
JP:4582	Symbio Pharmaceuticals Limited	44.00	-71.00	-61.74%
JP:4883	Modalis Therapeutics Corporation	28.00	-47.00	-62.67%
JP:7079	WDB coco Co., Ltd.	2550.00	-23.81	-0.93%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 15, 2026

Cyfuse Biomedical K.K. AI Stock Analysis